摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-pyridin-2-ylthiazolo[3,2-a]benzimidazole

中文名称
——
中文别名
——
英文名称
2-pyridin-2-ylthiazolo[3,2-a]benzimidazole
英文别名
2-(2-Pyridyl)thiazolo[3,2-a]benzimidazole;2-pyridin-2-yl-[1,3]thiazolo[3,2-a]benzimidazole
2-pyridin-2-ylthiazolo[3,2-a]benzimidazole化学式
CAS
——
化学式
C14H9N3S
mdl
——
分子量
251.312
InChiKey
PYSYZCQPKTULRN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    58.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    2-mercapto-1-[2-oxo-2-(pyridin-2-yl)ethyl]benzimidazole 以 PPA 为溶剂, 生成 2-pyridin-2-ylthiazolo[3,2-a]benzimidazole
    参考文献:
    名称:
    Thiazolo- and thiazino-benzimidazoles, and their use as
    摘要:
    本发明涉及一种治疗哺乳动物溃疡或过度分泌的方法,其包括给哺乳动物投与式为##STR1##或其药学上可接受的盐,其中--B--B.sup.1--代表公式--CR.sup.5.dbd.CR.sup.6--(Ib)或--(CHR.sup.5).sub.n--CR.sup.6.dbd.(Ic)的链;R代表可选择取代的芳基或杂环基;R.sup.1、R.sup.2、R.sup.3和R.sup.4分别代表氢或定义的取代基,或任何相邻的R.sup.1、R.sup.2、R.sup.3和R.sup.4成对地与它们所连接的碳原子组成一个五元或六元饱和或不饱和的碳环或杂环,该环可选择地被定义的取代基取代,所述的杂环中至少有一个异原子,所述异原子选自氧、氮和硫。本发明还公开了新的组合物和公式I的化合物。
    公开号:
    US04725605A1
点击查看最新优质反应信息

文献信息

  • 一种合成2-取代噻唑并[3,2-a]苯并咪唑类化 合物的方法
    申请人:温州大学
    公开号:CN109467564B
    公开(公告)日:2021-04-16
    本方法涉及一种合成2‑取代噻唑并[3,2‑a]苯并咪唑类化合物的方法。一种合成2‑取代噻唑并[3,2‑a]苯并咪唑类化合物的方法,以末端炔烃和2‑巯基苯并咪唑类化合物为原料,以铜盐为催化剂,以1,10‑菲罗啉衍生物作为配体,在碘单质、碱性物质存在的条件下,在有机溶剂中反应得到反应液,反应后经过后处理即得到2‑取代噻唑并[3,2‑a]苯并咪唑类化合物。本发明公开的合成2‑取代噻唑并[3,2‑a]苯并咪唑类化合物的方法适用于多种不同类型的炔烃,反应条件温和,操作简便,原子经济性高,反应放大至克级规模时仍可实现高效率高选择性的转化,符合绿色环保、经济高效的要求,在药物合成上具有较大的实际应用价值。
  • Copper-catalyzed aminothiolation of terminal alkynes with tunable regioselectivity
    作者:Jinqiang Kuang、Yuanzhi Xia、An Yang、Heng Zhang、Chenliang Su、Daesung Lee
    DOI:10.1039/c8cc09122f
    日期:——
    A simple, mild, and efficient catalytic aminothiolation of terminal alkynes for the synthesis of both 2- and 3-substituted thiazolo[3,2-a]benzimidazoles is established upon catalysis with copper(I), in which complementary regioselectivities could be achieved by using sterically different phenanthroline-based ligands.
    通过铜(I)催化建立了一种简单,温和且有效的末端炔烃催化氨基巯基化反应,用于合成2-和3-取代的噻唑并[3,2- a ]苯并咪唑,其中可通过以下方法实现互补的区域选择性:使用空间不同的基于菲咯啉的配体。
  • Thiazino-benzimidazoles and their use as antiulcer agents
    申请人:John Wyeth & Brother Limited
    公开号:US04786636A1
    公开(公告)日:1988-11-22
    This invention relates to a method of treating ulcers or hypersecretion in a mammal which comprises administering a compound of formula ##STR1## or a pharmaceutically acceptable salt thereof wherein --B--B.sup.1 - represents a chain of formula --CR.sup.5 .dbd.CR.sup.6 -- (Ib) or --(CHR.sup.5).sub.n --CR.sup.6 .dbd. (Ic); R represents an optionally substituted aryl or heteroaryl radical; R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, or a defined substituent or any adjacent pair of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together with the carbon atoms to which they are attached complete a five or six membered saturated or unsaturated carbocyclic or heterocyclic ring, said ring being optionally substituted by a defined substituent said heterocyclic ring having at least one heteroatom selected from oxygen, nitrogen and sulphur. Novel compositions and compounds of formula I are also disclosed.
    本发明涉及一种治疗哺乳动物溃疡或高分泌的方法,包括给哺乳动物注射以下化合物之一或其药学上可接受的盐:##STR1## 其中--B--B.sup.1-代表式为--CR.sup.5.dbd.CR.sup.6--(Ib)或--(CHR.sup.5).sub.n--CR.sup.6.dbd.(Ic)的链;R代表可选择取代的芳基或杂环芳基基团;R.sup.1、R.sup.2、R.sup.3和R.sup.4独立地代表氢,或者定义的取代基,或者任何相邻的R.sup.1、R.sup.2、R.sup.3和R.sup.4成对地与它们所连接的碳原子一起形成一个五元或六元饱和或不饱和碳环或杂环,所述环可选择取代一个定义的取代基,所述杂环至少有一个从氧、氮和硫中选择的杂原子。本发明还公开了新的I式化合物和组合物。
  • Thiazolo- and thiazino- benzimidazoles and their use as anti-ulcer agents
    申请人:John Wyeth & Brother Limited
    公开号:US04794123A1
    公开(公告)日:1988-12-27
    This invention relates to a method of treating ulcers or hypersecretion in a mammal which comprises administering a compound of formula ##STR1## or a pharmaceutically acceptable salt thereof wherein --B--B.sup.1 -- represents a chain of formula --CR.sup.5 .dbd.CR.sup.6 -- (Ib) or --(CHR.sup.5).sub.n --CR.sup.6 .dbd. (Ic); R represents an optionally substituted aryl or heteroaryl radical; R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, or a defined substituent or any adjacent pair of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together with the carbon atoms to which they are attached complete a five or six membered saturated or unsaturated carbocyclic or heterocyclic ring, said ring being optionally substituted by a defined substituent said heterocyclic ring having at least one heteroatom selected from oxygen, nitrogen and sulphur. Novel compositions and compounds of formula I are also disclosed.
    本发明涉及一种治疗哺乳动物溃疡或过度分泌的方法,该方法包括给哺乳动物施用式为##STR1##或其药学上可接受的盐,其中--B--B.sup.1--表示式为--CR.sup.5.dbd.CR.sup.6--(Ib)或--(CHR.sup.5).sub.n--CR.sup.6.dbd.(Ic)的链;R代表可选择取代的芳基或杂环芳基基团;R.sup.1、R.sup.2、R.sup.3和R.sup.4独立地代表氢,或定义的取代基,或任何相邻的R.sup.1、R.sup.2、R.sup.3和R.sup.4成对地与它们所附着的碳原子一起形成五元或六元饱和或不饱和碳环或杂环,所述环可选择取代,所述杂环至少有一个从氧、氮和硫中选择的杂原子。还公开了新的式I的组合物和化合物。
  • Thiazolo - and thiazinobenzimidazoles
    申请人:JOHN WYETH & BROTHER LIMITED
    公开号:EP0129409A2
    公开(公告)日:1984-12-27
    This invention relates to pharmaceutical compositions comprising compounds of formula or a pharmaceutically acceptable saltthereofwherein-B-B1- represents a chain of formula or or R represents an optionally substituted aryl or heteroaryl radical, R', R2, R3 and R4 independently represent hydrogen, or a defined substituent or any adjacent pair of R', R2, R3 and R4 together with the carbon atoms to which they are attached complete a five or six membered saturated or unsaturated carbocyclic or heterocyclic ring, said ring being optionally substituted by a defined substituentand said heterocyclic ring having at least one heteroatom selected from oxygen, nitrogen and sulphur; R5 and R6 independently represent hydrogen or lower alkyl; n and m independently represent 0 or 1, providing that when -B-B'- has formula la, n is 1 and m is O then R is heteroaryl, the term "heteroaryl" means a monovalent aromatic heterocyclic group in which the ring heteroatom or atoms is/are selected from oxygen, nitrogen and sulphur; and a pharmaceutically acceptable carrier which have anti-uicer and/or anti-secretory activity. Novel compounds of formula I are also disclosed together with processes for preparing them.
    本发明涉及药物组合物,该药物组合物包含式 或其药学上可接受的盐,其中 B-B1- 代表式链 或 或 R 代表任选取代的芳基或杂芳基、 R'、R2、R3 和 R4 独立地代表氢,或一个定义的取代基,或任何相邻的一对 R'、R2、R3 和 R4 与它们所连接的碳原子一起组成一个五或六个成员的饱和或不饱和碳环或杂环,所述环可任选被一个定义的取代基取代,所述杂环具有至少一个选自氧、氮和硫的杂原子; R5和R6独立地代表氢或低级烷基;n和m独立地代表0或1,条件是当-B-B'-具有式la,n为1,m为O时,R为杂芳基,术语 "杂芳基 "指环杂原子选自氧、氮和硫的一价芳香杂环基团;以及具有抗尿酸和/或抗分泌活性的药学上可接受的载体。此外,还公开了式 I 的新型化合物及其制备方法。
查看更多